Studies have shown that AML cells with FLT3 mutations are more sensitive to XPO1 inhibitors than wild-type FLT3, and dual targeting of XPO1 and FLT3 can produce synergistic effects, significantly extending the survival of AML mice (Zhang et al., 2018). The gene discussed is FLT3; the disease is acute myeloid leukemia.